ReviewAnnals of Saudi medicine
18F-FDG PET/CT imaging in oncology.
Review in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diagnostic accuracy of 18F-FDG PET/CT scan in distant metastasis staging of non-small cell lung cancer: A meta-analysis.Medicine · 2026Pooled it
- Head-to-head comparison of the diagnostic performance betweenAbdominal radiology (New York) · 2024Pooled it
- A systematic review and meta-analysis of predictive and prognostic models for outcome prediction using positron emission tomography radiomics in head and neck squamous cell carcinoma patients.Cancer medicine · 2023Pooled it
- Head-to-head comparison ofFrontiers in oncology · 2023Pooled it
- Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet.Nature reviews. Cancer · 2026Review
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- Post-traumatic neuroma mimicking lymph node metastasis onQuantitative imaging in medicine and surgery · 2026Article
- Diagnostic Performance of Post-Treatment F-18 FDG PET/CT for Detecting Recurrent Cervical Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Metabolic modelling and time-resolved mapping of glucose oxidative metabolism in the rat brain by indirect deuterium detection withMagma (New York, N.Y.) · 2026Article
- Complementary roles of 68Ga-FAPI and 18 F-FDG PET/CT in evaluating IgG4-related disease: a systematic review and pooled analysis.EJNMMI research · 2026Review
- Time-Driven Survival Analysis from FDG-PET/CT in Non-Small Cell Lung Cancer.Annals of biomedical engineering · 2026Article
- Comparative analysis ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview.Thoracic cancer · 2026Review
- Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Article
- Total-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Updated evidence on the accuracy ofQuantitative imaging in medicine and surgery · 2026Review
- New Sparks and Spots: Molecular Imaging with Positron Emission Tomography Will Change Management of Cushing's Disease.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- Quantitative dynamic granzyme B PET imaging to characterize novel combination immunotherapy response in preclinical glioblastoma models.Theranostics · 2026Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate diagnosis and staging are essential for the optimal management of cancer patients. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. It is a valuable tool for staging and restaging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques. It also allows for monitoring response to therapy and permitting timely modification of therapeutic regimens. In about 27% of the patients, the course of management is changed. This review provides guidance for oncologists/radiotherapists and clinical and surgical specialists on the use of 18F-FDG PET/CT in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.